Free Trial

Cadrenal Therapeutics (CVKD) Competitors

Cadrenal Therapeutics logo
$14.13 +0.36 (+2.61%)
Closing price 10/24/2025 03:52 PM Eastern
Extended Trading
$13.89 -0.24 (-1.70%)
As of 10/24/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVKD vs. CRDL, ENTX, EXOZ, COYA, IMMX, ATNF, ATYR, QNCX, ORMP, and SCLX

Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Cardiol Therapeutics (CRDL), Entera Bio (ENTX), eXoZymes (EXOZ), Coya Therapeutics (COYA), Immix Biopharma (IMMX), 180 Life Sciences (ATNF), aTyr Pharma (ATYR), Quince Therapeutics (QNCX), Oramed Pharmaceuticals (ORMP), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry.

Cadrenal Therapeutics vs. Its Competitors

Cadrenal Therapeutics (NASDAQ:CVKD) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.95 beat Cardiol Therapeutics' score of 0.50 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cadrenal Therapeutics Positive
Cardiol Therapeutics Neutral

Cadrenal Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.59
Cardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.50

Cardiol Therapeutics' return on equity of -232.26% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cadrenal TherapeuticsN/A -265.37% -196.38%
Cardiol Therapeutics N/A -232.26%-158.19%

Cadrenal Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 126.47%. Cardiol Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 572.27%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Cadrenal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cadrenal Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cardiol Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

Cardiol Therapeutics beats Cadrenal Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVKD vs. The Competition

MetricCadrenal TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$28.18M$3.42B$6.24B$10.69B
Dividend YieldN/A2.27%5.72%4.82%
P/E Ratio-1.5927.6331.3430.83
Price / SalesN/A461.42562.89174.99
Price / CashN/A46.1437.0861.44
Price / Book3.3910.4012.056.61
Net Income-$10.65M-$52.83M$3.33B$277.10M
7 Day Performance3.67%2.10%1.93%2.56%
1 Month Performance-0.49%12.33%7.77%3.77%
1 Year Performance-10.51%14.14%56.40%33.01%

Cadrenal Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVKD
Cadrenal Therapeutics
3.2632 of 5 stars
$14.13
+2.6%
$32.00
+126.5%
-15.7%$28.18MN/A-1.594Analyst Forecast
CRDL
Cardiol Therapeutics
2.1945 of 5 stars
$1.24
+17.6%
$8.00
+547.8%
-36.7%$107.13MN/A-3.6020News Coverage
Analyst Forecast
High Trading Volume
ENTX
Entera Bio
2.1136 of 5 stars
$2.33
-5.8%
$10.00
+329.9%
+22.0%$106.21M$180K-8.9520News Coverage
Positive News
Analyst Forecast
EXOZ
eXoZymes
0.3107 of 5 stars
$12.59
+3.2%
N/AN/A$105.63M$70K0.0029News Coverage
Analyst Forecast
COYA
Coya Therapeutics
2.7809 of 5 stars
$6.32
-1.5%
$16.20
+156.5%
-36.4%$105.12M$423.45K-5.076News Coverage
Analyst Forecast
Gap Down
IMMX
Immix Biopharma
3.3859 of 5 stars
$3.13
+1.8%
$8.00
+156.0%
+127.0%$103.73MN/A-4.089Positive News
Analyst Forecast
High Trading Volume
ATNF
180 Life Sciences
N/A$17.12
+1.9%
N/AN/A$103.39MN/A-1.147Gap Up
ATYR
aTyr Pharma
3.06 of 5 stars
$1.05
+2.5%
$23.25
+2,124.9%
-70.2%$103.38M$230K-1.3253Trending News
Analyst Forecast
QNCX
Quince Therapeutics
3.5591 of 5 stars
$1.81
-2.2%
$8.14
+349.9%
+47.9%$97.22MN/A-1.6660Analyst Forecast
ORMP
Oramed Pharmaceuticals
0.549 of 5 stars
$2.36
+2.8%
N/A+1.3%$96.56M$1.34M-6.7310News Coverage
Analyst Forecast
SCLX
Scilex
2.587 of 5 stars
$13.83
-1.8%
$630.00
+4,455.3%
-47.8%$96.24M$44.24M-0.4880Positive News
Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:CVKD) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners